CAROLINE M. TANNER, M.D.; HAROLD L. KLAWANS, M.D.
TANNER CM, KLAWANS HL. Pergolide Mesylate: New Therapy for Parkinson Disease. Ann Intern Med. 1982;96:522-523. doi: 10.7326/0003-4819-96-4-522
Download citation file:
Published: Ann Intern Med. 1982;96(4):522-523.
The side effects of chronic levodopa therapy are rarely as disabling as Parkinson disease itself. Many patients, however, after years of levodopa therapy at doses needed to control parkinsonism, are disabled by dyskinesias or psychoses. Others experience a progressive shortening of levodopa's effect (reduced "on" time) after each dose or sudden, freezing episodes (the "on/off" phenomenon) not related to dose. These therapeutic difficulties have encouraged a search for other antiparkinsonian agents. Because the primary neurohumoral defect in patients with Parkinson disease is loss of striatal dopamine, much research has focused on direct-acting dopamine agonists.
Pergolide mesylate, a synthetic cousin of
Learn more about subscription options.
Register Now for a free account.
Neurology, Parkinson's Disease.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only